Redmile Group Portfolio Changes in Q2 2026: Major Sells and New Investments

As of June 30th, 2026, Redmile Group LLC has reported changes to its investment portfolio. The firm's holdings saw notable shifts this quarter, characterized by significant reductions across several stocks and the initiation of new positions.

Major Reductions in Portfolio Holdings

Redmile Group significantly reduced its stake in SCHOLAR ROCK HLDG CORP (SRRK), a holding that previously accounted for 15.92% of the portfolio, dropping by -4755529 shares or -52.45%. This substantial decrease was not isolated; other large holdings also saw significant reductions.

Among these were NURIX THERAPEUTICS INC (NRIX), which decreased in value from its previous allocation of 6.64% to a new portfolio percentage allocation, with the share reduction being -3659021 shares or -47.32%. Similarly, ANNEXON INC (ANNX) experienced a notable decline, reducing by -2679891 shares (-18.42%) and adjusting its portfolio weight from 4.55%.

Furthermore, the firm exited its position in REGENXBIO INC (RGNX), which saw no change in shares held this quarter but was removed entirely from the list of holdings with a -0% allocation now shown. IMMUNOME INC (IMNM) also experienced a significant reduction (-647295 shares, -11.64%) and its portfolio weight decreased to 6.99%, down from previous levels.

New Positions Acquired

Concurrently with these exits and reductions, Redmile Group established new positions in several companies during Q2 2026. CLIMB BIO INC (ELYM) is one such example, where the firm increased its holdings by a full -1226330 shares or +100%, boosting its portfolio allocation to 1.07%.

AURA BIOSCIENCES INC (AURA) also entered the portfolio with an increase of +1666667 shares (+100%) from a prior period, contributing -0.79% to Redmile Group's current holdings structure. Similarly, SHATTUCK LABS INC (STTK) saw its allocation rise by +24.41%, adding another layer to the investor's portfolio.

Other Notable Changes and Portfolio Context

The changes observed in Redmile Group's portfolio are part of a broader trend indicated by several metrics. The holding count increased slightly this quarter, now standing at 33 positions according to available data.

ABSCI CORPORATION (ABSI) experienced a reduction (-1513641 shares, -18.34%) and its portfolio allocation dropped from previous levels to 5.24%. STOKE THERAPEUTICS INC (STOK) also saw a decrease of -218200 shares (-5.24%), lowering its weight in the portfolio.

ALX ONCOLOGY HLDGS INC (ALXO), despite being added to the portfolio, showed signs of ongoing adjustment with a slight reduction (-7.36% change) this quarter. Other companies like COGENT BIOSCIENCES INC (COGT) and IDEAYA BIOSCIENCES INC (IDYA) also changed hands but saw their allocations remain relatively small.

The portfolio indicators suggest active management, including ongoing adjustments to positions and the initiation of new ones. Redmile Group has a history of both large buys and sells as shown by this filing's metadata.